We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Seegene Reveals New Real-Time PCR at AACC 2014

By LabMedica International staff writers
Posted on 29 Jul 2014
Seegene Inc. More...
(Eschborn, Germany), a developer of multiplex PCR technologies, revealed their “MuDT” technology at the AACC 2014 meeting. MuDT is a real-time polymerase chain reaction (PCR) technology that will cause a shift in the PCR instrument market. The technology doubles the multiplexing capacity of any existing real-time PCR instrument––thus maximizing the value of the installed base of these instruments.

MuDT technology can be applied to any existing real-time PCR instrument and transforms it into a more powerful system by doubling its multiplexing capacity without upgrading the hardware.

The biotechnology industry has relied on real-time PCR for at least 20 years a molecular diagnostics technology, because of its versatility, speed, and ease of use. Despite many attempts, the biotechnology industry has not made significant advances that satisfy the growing demand for increased multiplexing and target quantification using limited numbers of channels in a single tube. Even melt curve analysis, after amplification has many disadvantages, such as end-point analysis after amplification, extended turnaround time, lack of quantification, and melt temperature variation due to target sequence variations on probe binding regions.

Additional benefits of the technology include: easier detection of multiple targets in a single channel without requiring melt curve analysis after amplification, SNP genotyping (homozygous wild type or mutant, or heterozygous) in a single channel.

Seegene is a global developer of multiplex molecular technologies and multiplex clinical molecular diagnostics that can simultaneously detect multiple targets with sensitivity, specificity, and reproducibility. The company's products detect multipathogens with good reliability and throughput, ultimately providing an economical basis for saving time, labor, and cost.

Related Links:

Seegene 



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Automated Microscope
dIFine
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.